• OPEN AN ACCOUNT
Indian Indices
Sensex
85,257.39 36.79
( 0.04%)
Global Indices
Nasdaq
48,085.52 -302.55
(-0.63%)
Dow Jones
6,867.73 -49.51
(-0.72%)
Hang Seng
50,384.39 -142.53
(-0.28%)
Nikkei 225
9,931.38 -9.33
(-0.09%)
Forex
USD-INR
89.84 -0.06
(-0.06%)
EUR-INR
105.67 -0.12
(-0.11%)
GBP-INR
121.20 -0.12
(-0.10%)
JPY-INR
0.58 0.00
(-0.05%)

EQUITY - MARKET SCREENER

Synoptics Technologies Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
73365
INE0BTR01012
82.3435142
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SYNOPTICS
12.52
50.54
EPS(TTM)
Face Value()
Div & Yield %
4.76
10
0
 

Zydus enters into licensing and commercialization agreement with RK Pharma Inc.
Nov 26,2025
Zydus Lifesciences has entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.

Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US.

The product, developed under the 505(b)(2) pathway, is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals.